ReviewRadiology2014
State of the art: Response assessment in lung cancer in the era of genomic medicine.
Review in Radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.BMC medical imaging · 2017Pooled it
- AI-Guided Delineation of Gross Tumor Volume for Body Tumors: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- [Advancements in Radiomics for Immunotherapy of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- A histogram of [EJNMMI research · 2024Article
- Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer:AJR. American journal of roentgenology · 2023Review
- Advances in Thoracic Imaging: Key Developments in the Past Decade and Future Directions.Radiology · 2023Article
- Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- State of the Art: Lung Cancer Staging Using Updated Imaging Modalities.Bioengineering (Basel, Switzerland) · 2022Review
- Article
- Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.The oncologist · 2022Review
- Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma.Radiology · 2022Article
- Does CCL19 act as a double-edged sword in cancer development?Clinical and experimental immunology · 2022Review
- Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Article
- Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.Lung cancer (Amsterdam, Netherlands) · 2020Review
- Radiomic features of primary tumor by lung cancer stage: analysis inTranslational lung cancer research · 2020Article
- Dual-energy computed tomography for pre-surgical identification of adenocarcinoma subtypes.Translational lung cancer research · 2020Article
- Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2020Article
- Tumor volume dynamics and tumor growth rate inEuropean journal of radiology open · 2020Article
- 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art.Current radiopharmaceuticals · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Tumor response assessment has been a foundation for advances in cancer therapy. Recent discoveries of effective targeted therapy for specific genomic abnormalities in lung cancer and their clinical application have brought revolutionary advances in lung cancer therapy and transformed the oncologist's approach to patients with lung cancer. Because imaging is a major method of response assessment in lung cancer both in clinical trials and practice, radiologists must understand the genomic alterations in lung cancer and the rapidly evolving therapeutic approaches to effectively communicate with oncology colleagues and maintain the key role in lung cancer care. This article describes the origin and importance of tumor response assessment, presents the recent genomic discoveries in lung cancer and therapies directed against these genomic changes, and describes how these discoveries affect the radiology community. The authors then summarize the conventional Response Evaluation Criteria in Solid Tumors and World Health Organization guidelines, which continue to be the major determinants of trial endpoints, and describe their limitations particularly in an era of genomic-based therapy. More advanced imaging techniques for lung cancer response assessment are presented, including computed tomography tumor volume and perfusion, dynamic contrast material-enhanced and diffusion-weighted magnetic resonance imaging, and positron emission tomography with fluorine 18 fluorodeoxyglucose and novel tracers. State-of-art knowledge of lung cancer biology, treatment, and imaging will help the radiology community to remain effective contributors to the personalized care of lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.